A basket trial of DS-8201a, a novel HER2-targeted antibody-drug conjugate, for HER2 amplified solid tumors identified by ctDNA analysis
Latest Information Update: 30 Apr 2025
At a glance
- Drugs Trastuzumab-deruxtecan (Primary)
- Indications Biliary cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Salivary gland cancer; Solid tumours
- Focus Therapeutic Use
- Acronyms HERALD
Most Recent Events
- 24 Apr 2025 According to Daiichi Sankyo Media release, Based on data from four phase 2 trials including HERALD,DESTINY-PanTumor02, DESTINY-CRC02 and DESTINY-Lung01,the company has submitted a supplemental New Drug Application (sNDA) to Japans Ministry of Health, Labour and Welfare (MHLW) for ENHERTU(trastuzumab deruxtecan) for the treatment of adult patients with HER2 positive advanced or recurrent solid tumors refractory or intolerant to standard treatments.
- 04 Jul 2023 Status changed to completed, as per JapicCTI record
- 06 Jun 2023 Results (at data cut-off: July 17, 2022), presented at the 59th Annual Meeting of the American Society of Clinical Oncology